MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Sy… (NCT04244916) | Clinical Trial Compass
TerminatedNot Applicable
MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis
Stopped: Departure of the coordinator
France2 participantsStarted 2020-05-25
Plain-language summary
To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of systemic sclerosis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Systemic sclerosis meeting the ACR / EULAR criteria of 2013
* Equal or more than 18 years old, able to freely consent to study
* In patients treated for skin damage:
* Diffuse skin sclerosis (rising above the elbows and / or knees)
* First clinical sign of systemic sclerosis outside of Raynaud's phenomenon going back less than three years
* Failure to take other concomitant immunosuppressive treatments or in the last 3 months except corticosteroids.
* In patients treated for lung damage:
* Interstitial lung damage identified on chest CT, chest x-ray
* Any duration of progression of systemic scleroderma
* Prescription of MMF in first line or in relay of a treatment with Cyclophosphamide.
* Absence of biotherapy in the last 6 months.
Exclusion Criteria:
\-